Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Acetylator polymorphism in Parkinson's disease.

J M Ladero1, F J Jimenez, J Benitez

  • 1Department of Medicine, University Complutense of Madrid, Spain.

European Journal of Clinical Pharmacology
|January 1, 1989
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Implementation of clopidogrel pharmacogenetics: a Brazilian perspective.

Pharmacogenomics·2025
Same author

Elevated CYP2C19 expression is associated with depressive symptoms and hippocampal homeostasis impairment.

Molecular psychiatry·2017
Same author

VEGF-related polymorphisms identified by GWAS and risk for major depression.

Translational psychiatry·2017
Same author

Elevated CYP2C19 expression is associated with depressive symptoms and hippocampal homeostasis impairment.

Molecular psychiatry·2016
Same author

High frequency of CYP2D6 ultrarapid metabolizers in Spain: controversy about their misclassification in worldwide population studies.

The pharmacogenomics journal·2016
Same author

Pharmacogenetic study of antipsychotic induced acute extrapyramidal symptoms in a first episode psychosis cohort: role of dopamine, serotonin and glutamate candidate genes.

The pharmacogenomics journal·2016

This study examined acetylator phenotype in Parkinson's disease patients. While slow acetylators showed lower sulphamethazine levels, acetylator polymorphism is not linked to Parkinson's disease risk.

Area of Science:

  • Pharmacogenetics
  • Neurology
  • Clinical Pharmacology

Background:

  • Acetylator phenotype, influenced by genetic variations, affects drug metabolism.
  • Parkinson's disease (PD) is a complex neurodegenerative disorder with potential genetic and environmental factors.
  • Understanding drug metabolism variations may offer insights into PD pathogenesis.

Purpose of the Study:

  • To investigate the association between acetylator phenotype and Parkinson's disease.
  • To compare sulphamethazine acetylation rates in PD patients and healthy controls.
  • To explore potential links between acetylator polymorphism and PD risk, onset, or clinical stage.

Main Methods:

  • Acetylator phenotype was determined using sulphamethazine.
  • 100 Parkinson's disease patients and 93 age-matched controls were studied.

Related Experiment Videos

  • Plasma levels of acetylated sulphamethazine were measured to classify phenotypes.

    • Main Results:

    • No significant relationship was found between acetylator polymorphism and age at onset or clinical stage of PD.
    • Among slow acetylators, plasma acetylated sulphamethazine was significantly lower in PD patients compared to controls.
    • Despite observed differences in acetylation among slow acetylators, no link to PD risk was supported.

    Conclusions:

    • Acetylator polymorphism does not appear to be a significant risk factor for developing Parkinson's disease.
    • Differences in sulphamethazine metabolism among slow acetylators warrant further investigation in PD.
    • This study suggests that pharmacogenetic variations in acetylation may not play a primary role in PD etiology.